elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q53569776-D380C668-1F6C-41B5-A883-FDC8F51F8B9E
Q53569776-D380C668-1F6C-41B5-A883-FDC8F51F8B9E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53569776-D380C668-1F6C-41B5-A883-FDC8F51F8B9E
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
P2860
Q53569776-D380C668-1F6C-41B5-A883-FDC8F51F8B9E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53569776-D380C668-1F6C-41B5-A883-FDC8F51F8B9E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0d19fb5072998da5a7173cf140d8b1e70e115f3d
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.